Newsroom > Articles


Paris, France, June 21st, 2021

Healcloud and Medexprim announce their strategic partnership dedicated to the analysis of clinical data for patient identification.

Medexprim, the European expert in generating regulatory-grade datasets of aggregated images and clinical data, builds bridges between hospitals and pharmaceutical companies to accelerate clinical research, and to pioneer new ways to design and execute clinical trials to dramatically reduce the associated time, cost, and risks.

Healcloud, a leading European technology enabler for life sciences research provides enterprise software to hospitals, clinical research organizations, and pharmaceutical companies, who would like to build virtual data networks that aggregate health Big Data with one tool to support clinical trials, observational studies, population health analytics, and pandemic monitoring.

This collaboration will expand both companies’ networks of hospitals, bring value to European hospitals and strengthen their research ecosystem. It will allow to answer pharmaceutical companies’ needs for patient identification for clinical trial.

Romain Cazavan, CEO of Medexprim, says: “We are very happy to announce our partnership with Healcloud, whose expertise is perfectly complementary with our ability to deliver complex homogeneous regulatory-grade datasets composed of clinical data, images, biology and genomics. Our collaboration will enable more European university hospitals to leverage their Real-World data in the service of clinical research and the well-being of patients.”

Chris Farkas, CEO of Healcloud, says: “By forging this strategic partnership with Medexprim, we empower both of our organizations to better fulfill the needs of our clients in pharmaceutical and life sciences research by offering a more comprehensive portfolio of services, a broader mix of GDPR-compliant data, including rich structured and unstructured clinical data complemented by imaging, as well as additional clinical site coverage across Europe. We look forward to collaborating with our colleagues at Medexprim, adding significant value to our clients and clinical research partners.”

About Medexprim

Medexprim, based in Toulouse, Paris, London and Boston, is the European leader in imaging data and clinical data extraction to accelerate clinical research. An accelerator of hospital clinical research and a tool for leveraging the data of its partner hospitals, Medexprim helps pharmaceutical companies access specific datasets and design more successful, cost effective and faster clinical trials, through a network of European academic hospitals and global data partners. With R-WiDE Strategy (From Real-World Imaging Data to Evidence), Medexprim wants to address clinical trial efficiency for pharma by delivering synthetic patients. –

For more information, please contact:

Anne-Sophie Labeta, Media Relations:

About Healcloud

Based in Vienna and Budapest, Healcloud is a leading European technology enabler for life sciences research. By providing enterprise software to the pharmaceutical industry, clinical research organizations, and hospitals, Healcloud helps build virtual data networks that aggregate health Big Data. Its integrated healthcare data platform, Healinsight Enterprise, revolutionizes data collection and management for any disease by rendering longitudinal real-world evidence health data, while providing actionable insights into patient populations that lower costs and improve health outcomes. –

For more information, please contact:

Ioana Stupariu, Press and Industry contact:

BC Platforms acquires Medexprim, paving the way for Global Leadership…

BC Platforms, a global leader in healthcare data management and analytics, today announced it…

RSNA 2023: Medexprim brings European multi-imaging datasets to Innovation.

Medexprim, a leading European innovator in the field of Real-World Data and healthcare solutions,…

Medexprim appoints Doctor Mercedes Serra as Head of Data Science…

Medexprim is proud to announce the appointment of Mercedes Serra as the Head of…

IQVIA clôture l’édition 2023 de son Accelerator Program, en collaboration…

IQVIA, spécialiste mondial d’analyses avancées, de solutions technologiques et de services de recherche clinique…